22 September 2022 : Clinical Research
Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis
Meheroz H. Rabadi12ABCDEF*, Kimberly Just1B, Chao Xu
3CDE
DOI: 10.12659/MSM.938116
Med Sci Monit 2022; 28:e938116
Table 1 Demographics based on multiple sclerosis survival (dichotomized).
| Alive (n=223) | Dead (n=56) | p-value | |
|---|---|---|---|
| Mean (SD) | 49.3 (12.2) | 61.9 (10.0) | <0.001 |
| Mean (SD) | 21.4 (12.3) | 34.6 (13.3) | <0.001 |
| <10 | 34 (15.4%) | 1 (1.9%) | <0.001 |
| ≥10 and ≤19 | 73 (33.0%) | 5 (9.2%) | |
| ≥20 | 114 (51.6%) | 48 (88.9%) | |
| Mean (SD) | 8.15 (3.57) | 12.2 (3.36) | <0.001 |
| Relapsing remitting | 107 (48.9%) | 8 (15.1%) | <0.001 |
| Progressive (primary and secondary) | 78 (35.6%) | 42 (79.2%) | |
| Other (CIS RIS) | 30 (13.7%) | 1 (1.9%) | |
| Unclassified category | 4 (1.8%) | 2 (3.8%) | |
| Mean (SD) | 27.5 (3.13) | 25.6 (8.04) | 0.104 |
| Mean (SD) | 3.57 (2.81) | 6.73 (2.18) | <0.001 |
| 0–3 | 120 (55.8%) | 3 (7.1%) | <0.001 |
| 3.5–6 | 49 (22.8%) | 8 (19.1%) | |
| >6 | 46 (21.4%) | 31 (73.8%) | |
| Mean (SD) | 110 (21.1) | 81.4 (29.6) | <0.001 |
| 102 (48.6%) | 38 (70.4%) | 0.006 | |
| 30 (14.2%) | 19 (35.2%) | 0.001 | |
| Mean (SD) | 28.4 (5.27) | 25.7 (7.49) | 0.018 |
| (yes) | 142 (64.8%) | 33 (60.0%) | 0.532 |
| (yes) | 142 (66.4%) | 35 (81.4%) | 0.07 |
| Infusion | 17 (7.6%) | 1 (1.8%) | <0.001 |
| Injectables | 41 (18.4%) | 5 (8.9%) | |
| Never/none/other | 99 (44.4%) | 50 (89.3%) | |
| Oral | 66 (29.6%) | 0 (0%) | |
| DMT – disease modifying therapies; MS – multiple sclerosis; MMSE – Mini-Mental State Examination; TFIM – Total Functional Independence Measure; EDSS – Expanded Disability Scale Score. | |||